| |
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Today’s Big NewsNov 8, 2024 |
|
QPS has extensive expertise in the conduct of oncology clinical studies,
having successfully managed over 50 oncology studies globally.
Download the QPS Case Study to learn how QPS performed two global Phase III studies in prostate cancer patients. .+(1).png)
|
|
| By Conor Hale During quarterly earnings calls this week across the medtech industry, a recurring question has been on investors’ minds. |
|
|
|
By Nick Paul Taylor Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to a 33% response rate but also three deaths in heavily pretreated cancer patients. |
By Kevin Dunleavy The two most valuable companies in the biopharma industry, Eli Lilly and Novo Nordisk, experienced market cap declines in the third quarter. On the flip side, Bristol Myers Squibb, Gilead and Sanofi made significant gains. |
By Ayla Ellison,Gabrielle Masson,Andrea Park This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
By Zoey Becker Alteogen will use its human hyaluronidase hybridization platform to develop a subcutaneous formulation of the blockbuster antibody-drug conjugate. |
By Kevin Dunleavy A phase 3 study has shown that AstraZeneca and Amgen's Tezspire provided a statistically significant and clinically meaningful reduction in polyp size and nasal congestion in patients with severe chronic rhinosinusitis with nasal polyps. |
By Nick Paul Taylor NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate. The biotech has decided to seek partners for its existing clinical candidate and other preclinical programs to free up cash for its new priority. |
By Conor Hale J&J joins Medtronic and Boston Scientific in the rapidly growing sector for treating atrial fibrillation. |
By James Waldron AlloVir has been reeling after a trio of phase 3 trial failures last year led the company to shed almost all of its staff. Now, the immunotherapy biotech has found a new path forward by acquiring eye disease biotech Kalaris Therapeutics. |
By Angus Liu After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
|
|---|
|
|
|
Wednesday, November 13 , 2024 | 10am ET / 7am PT Join industry experts to gain insights pertinent to efficient and effective drug development. Understand and execute a risk-based critical thinking approach related to injectable drug packaging and delivery. Register now. 
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
